search
Back to results

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Primary Purpose

Mitochondrial Diseases

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Cysteamine Bitartrate
Sponsored by
Horizon Pharma USA, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mitochondrial Diseases focused on measuring Inherited mitochondrial disease, Leigh Syndrome, Leber's Hereditary Optic Neuropathy (LHON), Myoclonic epilepsy and ragged-red fibers (MERFF), Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS), Kearn-Sayre syndrome, Polymerase gamma (POLG) -related disorders, Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE)

Eligibility Criteria

6 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Completed all visits in Study RP103-MITO-001 (NCT02023866).
  2. Body weight ≥ 5 kg.
  3. The subject must be willing to abstain from initiating dietary supplements and non-prescribed medications except as allowed by the Investigator, throughout the study (from Day 1 to Study Exit).
  4. Willing and able to comply with study drug dosing requirements, i.e. ingest the RP103 capsules intact, or sprinkled in liquid or soft food, or using a G-tube.
  5. Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy]) must agree to utilize two of the following acceptable forms of contraception throughout the study (from Day 1 to Study Exit):

    • Hormonal contraception: birth control pills, injection, patch, vaginal ring or implant;
    • Condom or diaphragm, with spermicide;
    • Intrauterine device (IUD);
    • Sterile male partner (vasectomy performed at least 6 months prior to the study).
  6. Patient's legally authorized representative must provide written informed consent; Patient must provide assent, if required by local/institutional requirements.

Exclusion Criteria:

  1. Documented diagnosis of concurrent inborn errors of metabolism.
  2. Platelet count, lymphocyte count or hemoglobin below the lower limit of normal (LLN) at the Baseline visit.
  3. Hepatic insufficiency with liver enzyme tests (alkaline phosphatase, aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times the upper limit of normal (ULN) at the Baseline Visit.
  4. Bilirubin > 1.2 g/dL at the Baseline Visit.
  5. Inability to complete the elements of the study, e.g., coma, hemodynamic instability or requiring continuous ventilator support.
  6. Malabsorption requiring total parenteral nutrition (TPN), chronic diarrhea, bouts of pseudo obstruction.
  7. Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
  8. Patients with suspected elevated intracranial pressure, pseudotumor cerebri (PTC) and/or papilledema.
  9. Severe gastrointestinal disease including gastroparesis.
  10. History of drug or alcohol abuse.
  11. History of pancreatitis.
  12. Participated in an investigational drug trial (except the RP103-MITO-001 study) within 30 days or, within 90 days for a biologic, device, or surgical treatment, for inherited mitochondrial diseases prior to the Baseline Visit.
  13. Known or suspected hypersensitivity to cysteamine and penicillamine.
  14. Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or with a positive serum pregnancy test at the Baseline visit.
  15. Patients who, in the opinion of the Investigator, are not able or willing to comply with the protocol.

Sites / Locations

  • University of California at San Diego (UCSD)
  • Stanford University School of Medicine
  • Akron Children's Hospital
  • Baylor College of Medicine
  • University of Utah

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cysteamine Bitartrate Delayed-release

Arm Description

Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.

Outcomes

Primary Outcome Measures

Change in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Score
The NPMDS evaluates the progression of mitochondrial disease in pediatric patients in 4 domains: I - Current Function (vision, hearing, communication, feeding, and mobility) with scores ranging from 0 to 21; II - System Specific Involvement (seizures, encephalopathy, bleeding diathesis or coagulation defects, gastrointestinal, endocrine, respiratory, cardiovascular, renal, liver, and blood) with scores ranging from 0 to 30. III - Current Clinical Assessment (growth and development over past 6 months, vision, strabismus and eye movement, myopathy, ataxia, pyramidal, extrapyramidal, and neuropathy) with scores ranging from 0 to 28; IV - Quality of Life with scores ranging from 0 to 25. For sections I-III, higher scores reflect more severe disease. For Section IV, a higher score reflects a lower quality of life.

Secondary Outcome Measures

Change Over Time in Two of the Most Pre-eminent Symptoms
The two pre-eminent symptoms previously identified in study RP103-MITO-001 were to be continued to be assessed during the extension study. Symptoms included myopathy, dystonia, ataxia, retarded motor development, reduced activities of daily living, and vision.
Change Over Time in Pharmacodynamic Biomarkers
Change from baseline in glutathione, glutathione disulfide, and lactate analyses were not performed as the study was prematurely terminated.

Full Information

First Posted
June 10, 2015
Last Updated
April 13, 2018
Sponsor
Horizon Pharma USA, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02473445
Brief Title
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
Official Title
A Long-Term Open-Label Extension Study of RP103-MITO-001 to Assess the Safety, Tolerability and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Terminated
Why Stopped
Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.
Study Start Date
May 19, 2015 (Actual)
Primary Completion Date
March 6, 2017 (Actual)
Study Completion Date
March 6, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Horizon Pharma USA, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study RP103-MITO-001 (NCT02023866).
Detailed Description
Patients with inherited mitochondrial diseases associated with nuclear or mitochondrial deoxyribonucleic acid (DNA) mutations that impair the respiratory chain. These include, but are not limited to the following clinical syndromes: Leber's hereditary optic neuropathy; myoclonic epilepsy and ragged-red fibers (MERFF); mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS); Kearn-Sayre syndrome; subacute necrotizing encephalopathy (Leigh Syndrome); polymerase gamma (POLG)-related disorders (Alpers-Huttenlocher Syndrome, Autosomal Dominant Progressive External Ophthalmoplegia, Autosomal Recessive Progressive External Ophthalmoplegia, Childhood Myocerebrohepatopathy Spectrum Disorders, Myoclonic Epilepsy Myopathy Sensory Ataxia, POLG-Related Ataxia Neuropathy Spectrum Disorders); Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE), also called myoneurogastrointestinal encephalopathy syndrome or polyneuropathy-ophthalmoplegia-leukoencephalopathy- Intestinal pseudoobstruction (POLIP) syndrome; others, e.g., mitochondrial cardiomyopathies and other syndromes due to multiple mitochondrial DNA deletions. Patients completing study RP103-MITO-001 (NCT02023866) are eligible for enrollment into the extension study RP103-MITO-002 if all inclusion and exclusion criteria are fulfilled. Subjects continue on the last total daily dose of cysteamine bitartrate delayed-release capsules taken during RP103-MITO-001. Dose-adjustments are permitted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitochondrial Diseases
Keywords
Inherited mitochondrial disease, Leigh Syndrome, Leber's Hereditary Optic Neuropathy (LHON), Myoclonic epilepsy and ragged-red fibers (MERFF), Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS), Kearn-Sayre syndrome, Polymerase gamma (POLG) -related disorders, Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Open-label extension study
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cysteamine Bitartrate Delayed-release
Arm Type
Experimental
Arm Description
Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
Intervention Type
Drug
Intervention Name(s)
Cysteamine Bitartrate
Other Intervention Name(s)
RP103, PROCYSBI®
Intervention Description
Cysteamine Bitartrate Delayed-release capsules
Primary Outcome Measure Information:
Title
Change in Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Score
Description
The NPMDS evaluates the progression of mitochondrial disease in pediatric patients in 4 domains: I - Current Function (vision, hearing, communication, feeding, and mobility) with scores ranging from 0 to 21; II - System Specific Involvement (seizures, encephalopathy, bleeding diathesis or coagulation defects, gastrointestinal, endocrine, respiratory, cardiovascular, renal, liver, and blood) with scores ranging from 0 to 30. III - Current Clinical Assessment (growth and development over past 6 months, vision, strabismus and eye movement, myopathy, ataxia, pyramidal, extrapyramidal, and neuropathy) with scores ranging from 0 to 28; IV - Quality of Life with scores ranging from 0 to 25. For sections I-III, higher scores reflect more severe disease. For Section IV, a higher score reflects a lower quality of life.
Time Frame
Baseline, every 3 months and Study Exit (up to 24 Months)
Secondary Outcome Measure Information:
Title
Change Over Time in Two of the Most Pre-eminent Symptoms
Description
The two pre-eminent symptoms previously identified in study RP103-MITO-001 were to be continued to be assessed during the extension study. Symptoms included myopathy, dystonia, ataxia, retarded motor development, reduced activities of daily living, and vision.
Time Frame
Baseline, every 3 months and Study Exit (up to 24 Months)
Title
Change Over Time in Pharmacodynamic Biomarkers
Description
Change from baseline in glutathione, glutathione disulfide, and lactate analyses were not performed as the study was prematurely terminated.
Time Frame
Baseline, every 3 months and Study Exit (up to 24 Months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Completed all visits in Study RP103-MITO-001 (NCT02023866). Body weight ≥ 5 kg. The subject must be willing to abstain from initiating dietary supplements and non-prescribed medications except as allowed by the Investigator, throughout the study (from Day 1 to Study Exit). Willing and able to comply with study drug dosing requirements, i.e. ingest the RP103 capsules intact, or sprinkled in liquid or soft food, or using a G-tube. Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy]) must agree to utilize two of the following acceptable forms of contraception throughout the study (from Day 1 to Study Exit): Hormonal contraception: birth control pills, injection, patch, vaginal ring or implant; Condom or diaphragm, with spermicide; Intrauterine device (IUD); Sterile male partner (vasectomy performed at least 6 months prior to the study). Patient's legally authorized representative must provide written informed consent; Patient must provide assent, if required by local/institutional requirements. Exclusion Criteria: Documented diagnosis of concurrent inborn errors of metabolism. Platelet count, lymphocyte count or hemoglobin below the lower limit of normal (LLN) at the Baseline visit. Hepatic insufficiency with liver enzyme tests (alkaline phosphatase, aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times the upper limit of normal (ULN) at the Baseline Visit. Bilirubin > 1.2 g/dL at the Baseline Visit. Inability to complete the elements of the study, e.g., coma, hemodynamic instability or requiring continuous ventilator support. Malabsorption requiring total parenteral nutrition (TPN), chronic diarrhea, bouts of pseudo obstruction. Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis. Patients with suspected elevated intracranial pressure, pseudotumor cerebri (PTC) and/or papilledema. Severe gastrointestinal disease including gastroparesis. History of drug or alcohol abuse. History of pancreatitis. Participated in an investigational drug trial (except the RP103-MITO-001 study) within 30 days or, within 90 days for a biologic, device, or surgical treatment, for inherited mitochondrial diseases prior to the Baseline Visit. Known or suspected hypersensitivity to cysteamine and penicillamine. Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or with a positive serum pregnancy test at the Baseline visit. Patients who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evelyn Olson, BS
Organizational Affiliation
Horizon Pharma USA, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
University of California at San Diego (UCSD)
City
San Diego
State/Province
California
ZIP/Postal Code
92093-0935
Country
United States
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Akron Children's Hospital
City
Akron
State/Province
Ohio
ZIP/Postal Code
44308
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
20569301
Citation
Bousquet M, Gibrat C, Ouellet M, Rouillard C, Calon F, Cicchetti F. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J Neurochem. 2010 Sep;114(6):1651-8. doi: 10.1111/j.1471-4159.2010.06874.x. Epub 2010 Aug 19.
Results Reference
background
PubMed Identifier
22208644
Citation
Salmi H, Leonard JV, Rahman S, Lapatto R. Plasma thiol status is altered in children with mitochondrial diseases. Scand J Clin Lab Invest. 2012 Apr;72(2):152-7. doi: 10.3109/00365513.2011.646299. Epub 2012 Jan 2.
Results Reference
background
PubMed Identifier
18702664
Citation
Maher P, Lewerenz J, Lozano C, Torres JL. A novel approach to enhancing cellular glutathione levels. J Neurochem. 2008 Nov;107(3):690-700. doi: 10.1111/j.1471-4159.2008.05620.x. Epub 2008 Aug 12.
Results Reference
background
PubMed Identifier
19960200
Citation
Mancuso M, Orsucci D, Logerfo A, Rocchi A, Petrozzi L, Nesti C, Galetta F, Santoro G, Murri L, Siciliano G. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol. 2010 May;257(5):774-81. doi: 10.1007/s00415-009-5409-7. Epub 2009 Dec 4.
Results Reference
background

Learn more about this trial

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

We'll reach out to this number within 24 hrs